At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 121 enrolled
Drug / intervention
Benralizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO)
In Brief
A Phase 3 clinical trial evaluating Benralizumab for Asthma. Completed, enrolled 121 participants across 25 sites in 2 countries.
Detailed Summary
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionAug 2017
TodayJul 2026
First PostedSep 28, 2016
Enrollment StartNov 10, 2016
Primary CompletionAug 21, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago
Interventions
Benralizumabbiological
Benralizumab administered subcutaneously every 4 weeks